Novo Nordisk's semaglutide ... and Eli Lilly's Trulicity (dulaglutide). Semaglutide is also being developed as a once-weekly injection that has already been shown to provide good control of ...
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide ... compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold ...
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...
Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...
Novo Nordisk’s ... by its marketed semaglutide (GLP-1 agonist) medicines, marketed as Ozempic pre-filled pen and Rybelsus oral tablet for T2D and as Wegovy injection for weight management.
LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback